Somatostatin in Alzheimer's disease: A new Role for an Old Player
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The amyloid beta (Aβ) peptide is central to the pathogenesis of Alzheimer's disease (AD). Insights into Aβ-interacting proteins are critical for understanding the molecular mechanisms underlying Aβ-mediated toxicity. We recently undertook an in-depth in vitro interrogation of the Aβ1-42 interactome using human frontal lobes as the biological source material and taking advantage of advances in mass spectrometry performance characteristics. These analyses uncovered the small cyclic neuropeptide somatostatin (SST) to be the most selectively enriched binder to oligomeric Aβ1-42. Subsequent validation experiments revealed that SST interferes with Aβ fibrillization and promotes the formation of Aβ assemblies characterized by a 50-60 kDa SDS-resistant core. The distributions of SST and Aβ overlap in the brain and SST has been linked to AD by several additional observations. This perspective summarizes this body of literature and draws attention to the fact that SST is one of several neuropeptide hormones that acquire amyloid properties before their synaptic release. The latter places the interaction between SST and Aβ among an increasing number of observations that attest to the ability of amyloidogenic proteins to influence each other. A model is presented which attempts to reconcile existing data on the involvement of SST in the AD etiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
RetractedThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Gene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874
ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Davies, P., Katzman, R., & Terry, R. D. (1980) · Nature · doi:10.1038/288279a0 · Cited by 882
Chen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., Jagadapillai, R., Liu, R., Choe, K., Shivakumar, B., et al. (2016) · Scientific Reports · doi:10.1038/srep34477 · Cited by 463 · cited 2×
“suggested before [11,12], to date this scenario has not been adequately considered in the context of AD.”
BackgroundSomatostatin immunoreactivity in neuritic plaques of Alzheimer's patients
Morrison, J. H., Rogers, J., Scherr, S., Benoit, R., & Bloom, F. E. (1985) · Nature · doi:10.1038/314090a0 · Cited by 264 · cited 1×
“The first indication that SST may have a more intimate role in the AD pathogenesis emerged in histochemical studies, which detected processes of somatostatinergic neurons in immediate proximity to neuritic plaques in the cingulate, frontal and temporal cortices [23], as well as in the amygdala and hippocampus [24].”
BackgroundAmyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256
Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer’s disease
Saiz-Sanchez, D., De la Rosa-Prieto, C., Ubeda-Banon, I., & Martinez-Marcos, A. (2015) · Brain Structure and Function · doi:10.1007/s00429-014-0771-3 · Cited by 79
Cited by
GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
Consens, M. E., Chen, Y., Menon, V., Wang, Y., Schneider, J. A., De Jager, P. L., Bennett, D. A., Tripathy, S. J., & Felsky, D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.903175 · Cited by 44
Somatostatin, Olfaction, and Neurodegeneration
Saiz-Sanchez, D., Ubeda-Bañon, I., Flores-Cuadrado, A., Gonzalez-Rodriguez, M., Villar-Conde, S., Astillero-Lopez, V., & Martinez-Marcos, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00096 · Cited by 32
“Moreover, SST cells regulate neurons by subtractive inhibition, which enhances the threshold for sensory input to trigger a response, that is independent of odor identity and intensity (Sturgill and Isaacson, 2015).”
BackgroundBrooks, L. R. K., & Mias, G. I. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00392 · Cited by 32
“Also, STMN2 and SST have both previously been associated with expression reduction due to age(Solarski et al., 2018; Stelzer et al., 2016).”
BackgroundThe primary cilia are associated with the axon initial segment in neurons
Wang, H., Li, Y., Li, X., Sun, Z., Yu, F., Pashang, A., Kulasiri, D., Li, H. W., Chen, H., Hou, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202407405 · Cited by 13
Self-citation
Metadata
- Authors
- Solarski, M., Wang, H., Wille, H., & Schmitt-Ulms, G.
- Venue
- Prion
- Publisher
- Informa UK Limited
- Published
- 2018-01-02
- Volume
- 12
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1933-6896 (ISSN-L)
- 1933-690X
- OpenAlex
- W2773321573
- Cited by
- 62
- References
- 11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Somatostatin in Alzheimer's disease: A new Role for an Old Player. https://app.cochat.ai/papers/10.1080/19336896.2017.1405207
- The paper
- Solarski, M., Wang, H., Wille, H., & Schmitt-Ulms, G. (2018). Somatostatin in Alzheimer's disease: A new Role for an Old Player. Prion. https://doi.org/10.1080/19336896.2017.1405207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.